Clinical Trial Update: A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone [Phase 1]

View source ↗

Summary

Phase 1 dose-proportionality study evaluating five tablet strengths of ER OROS paliperidone to characterize pharmacokinetics in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ER OROS Paliperidone (paliperidone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED